186 related articles for article (PubMed ID: 33899960)
1. "Ex-vivo" T-cell depletion in allogeneic hematopoietic stem cell transplantation: New clinical approaches for old challenges.
Diaz MA; Gasior M; Molina B; Pérez-Martínez A; González-Vicent M
Eur J Haematol; 2021 Jul; 107(1):38-47. PubMed ID: 33899960
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic stem-cell transplantation from haploidentical donors using 'ex-vivo' T-cell depletion in pediatric patients with hematological malignancies: state of the art review.
González-Vicent M; Díaz Perez MA
Curr Opin Oncol; 2018 Nov; 30(6):396-401. PubMed ID: 30307414
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy.
Anandi P; Tian X; Ito S; Muranski P; Chokshi PD; Watters N; Chawla U; Hensel N; Stroncek DF; Battiwalla M; Barrett AJ
Cytotherapy; 2017 Jun; 19(6):735-743. PubMed ID: 28395942
[TBL] [Abstract][Full Text] [Related]
5. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
6. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic peripheral blood stem cell transplantation with CD34+-cell selection and delayed T-cell add-back in adults. Results of a single center pilot study.
Martino R; Martín-Henao G; Sureda A; Altés A; Canals C; Brunet S; Sierra J
Haematologica; 2000 Nov; 85(11):1165-71. PubMed ID: 11064469
[TBL] [Abstract][Full Text] [Related]
8. In-vivo or ex-vivo T cell depletion or both to prevent graft-versus-host disease after hematopoietic stem cell transplantation.
Busca A; Aversa F
Expert Opin Biol Ther; 2017 Nov; 17(11):1401-1415. PubMed ID: 28846051
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies.
Sohn SK; Jung JT; Kim DH; Lee NY; Seo KW; Chae YS; Park SW; Kim JG; Suh JS; Lee KB
Cancer; 2002 Jan; 94(1):18-24. PubMed ID: 11815956
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
Laport GG; Sheehan K; Baker J; Armstrong R; Wong RM; Lowsky R; Johnston LJ; Shizuru JA; Miklos D; Arai S; Benjamin JE; Weng WK; Negrin RS
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1679-87. PubMed ID: 21664472
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.
Montoro J; Roldán E; Piñana JL; Barba P; Chorão P; Quintero A; Hernani R; Ortí G; Lorenzo JI; Balaguer-Roselló A; Salamero O; Fox L; Solves P; Gómez I; Guerreiro M; Hernández Boluda JC; Sanz G; Solano C; Sanz MÁ; Valcárcel D; Sanz J
Eur J Haematol; 2021 Jan; 106(1):114-125. PubMed ID: 33025625
[TBL] [Abstract][Full Text] [Related]
12. The role of early natural killer cell adoptive infusion before engraftment in protecting against human herpesvirus-6B encephalitis after naïve T-cell-depleted allogeneic stem cell transplantation.
Gasior M; Ferreras C; de Paz R; Bueno D; Mozo Y; Sisinni L; Canizales JT; González B; Olivas-Mazón R; Marcos A; Romero AB; Constanzo A; Mirones I; Fernández-Arroyo A; Balas A; Vicario JL; Escudero A; Yuste VJ; Pérez-Martínez A
Transfusion; 2021 May; 61(5):1505-1517. PubMed ID: 33713461
[TBL] [Abstract][Full Text] [Related]
13. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.
Baron F; Siquet J; Schaaf-Lafontaine N; Baudoux E; Hermanne JP; Fillet G; Beguin Y
Haematologica; 2002 Jan; 87(1):78-88. PubMed ID: 11801468
[TBL] [Abstract][Full Text] [Related]
14. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
Huang X; Liu D
Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
[TBL] [Abstract][Full Text] [Related]
15. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
16. A retrospective Dutch study comparing T cell-depleted allogeneic blood stem cell transplantation vs T cell-depleted allogeneic bone marrow transplantation.
Cornelissen JJ; Fibbe WE; Schattenberg AV; Petersen EJ; Willemze R; de Witte TJ; Löwenberg B; Verdonck LF; vd Biezen A; Brand R
Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S66-70. PubMed ID: 9712499
[TBL] [Abstract][Full Text] [Related]
17. Prevention of GVHD without losing GVL effect: windows of opportunity.
Zhang P; Chen BJ; Chao NJ
Immunol Res; 2011 Apr; 49(1-3):49-55. PubMed ID: 21136200
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation.
Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; García-Latorre E; Moreno-Lafont M; Estrada-García I; Montiel-Cervantes L; Tripp-Villanueva F; Ayala-Sánchez M; García-León LD; Borbolla-Escoboza JR; Mayani H
Ann Hematol; 2006 Feb; 85(2):113-20. PubMed ID: 16311734
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
20. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.
Ferrá C; Rodríguez-Luaces M; Gallardo D; Encuentra M; Martín-Henao GA; Peris J; Ancín I; Sarrá J; Berlanga JJ; García J; Grañena A
Bone Marrow Transplant; 2001 Nov; 28(10):963-8. PubMed ID: 11753552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
